Jakarta - PT Esa Medika Mandiri Tbk (EMMI) is preparing to list on\nthe Indonesia Stock Exchange (BEI) through an Initial Public Offering\n(IPO) scheme. The company, which operates in the wholesale trade of\nlaboratory, pharmaceutical, and medical equipment, is aiming to raise\nfresh funds to strengthen its capital structure and support working\ncapital. Below is an in-depth review of EMMI\u2019s prospectus, covering\nfinancial performance trends, operational ratios, and an analysis of\npositive catalysts as well as the company\u2019s business risks.<\/p>\n
Based on prospectus data, EMMI recorded a solid year-on-year (YoY)\nfinancial performance growth trend. The significant increase in revenue\nin 2024 and 2025 was primarily driven by the acquisition of large-scale\nprocurement contracts financed by international donor agencies.<\/p>\n
In terms of revenue structure, EMMI has a very massive exposure to\ngovernment projects. Sales realisation in 2025 was almost entirely\nsourced from state health agency tenders, while the portion of sales to\nthe non-government segment was relatively minimal. Although the\nprospectus does not detail the historical revenue portion by product\ntype, the focus of EMMI\u2019s business lines can be clearly mapped through\nthe allocation of IPO funds for working capital for inventory purchases.\nThe company is allocating approximately IDR 165 billion specifically to\nsecure stock of critical medical device products. Electro Cauters and\nvarious surgical instruments are the most dominant portfolio being\nprepared to meet the demand of healthcare facilities.<\/p>\n
Through this corporate action, the company is targeting maximum fund\nraising of IDR 269.27 billion. The majority of the IPO proceeds will be\nallocated for working capital needs and the settlement of part of its\nbank debt obligations.<\/p>\n
As the lead underwriter, PT BRI Danareksa Sekuritas has a fairly\nvaried portfolio in guiding issuers to list on the exchange. Based on\nthe history of several recent IPOs it has handled, the majority of share\nprice movements on the first day of trading opening recorded positive\nresults, although some recorded slight weakness due to market\ndynamics.<\/p>\n
EMMI\u2019s overall financial metrics show consistent improvement from\nyear to year. The company\u2019s ability to generate net operating profit\nagainst sales surged to a level of 7.14% in 2025. In terms of solvency,\nthe debt-to-equity ratio (DER) was massively reduced from a position of\n5.08x in 2023 to 2.89x in 2025. On the other hand, the Interest Coverage\nRatio (ICR) rose to a level of 2.47x, indicating a healthier capacity to\ncover interest expenses, although the Current Ratio (0.92x) still\nrequires short-term liquidity strengthening to meet bank covenant\nrequirements.<\/p>\n
The sustainability prospects of EMMI\u2019s business are supported by the\ncompany\u2019s track record in securing contracts from international-scale\ninstitutions. In addition to acting as an exclusive distributor, EMMI is\nbeginning to develop a consumable goods business segment through the\nmanufacture of surgical sutures in cooperation with a global entity.\nThis strategic initiative is expected to strengthen recurring income\nsources in the future.<\/p>\n
From a risk profile perspective, investors need to scrutinise the\nrevenue structure concentrated on the government segment. This condition\nplaces the company\u2019s cash flow in a position vulnerable to adjustments\nin the State Budget (APBN) allocation. Coupled with the fact that the\nmajority of E-Catalogue procurement sales are not based on long-term\ncontracts, the stability of EMMI\u2019s revenue has the potential to\nexperience fluctuations.<\/p>", "url": "https:\/\/jawawa.id\/newsitem\/emmi-eyes-ipo-soaring-profits-but-overly-dependent-on-government-1782967859", "image": "" }, "sponsor": "Okusi Associates", "sponsor_url": "https:\/\/okusiassociates.com" }